{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:10Z","timestamp":1792131010166,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40263-018-0575-8","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T12:20:05Z","timestamp":1538137205000},"page":"1159-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential"],"prefix":"10.1007","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct01721161","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alexander","family":"Klistorner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"RENEW MF-VEP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Garrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Vanopdenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo S\u00e1nchez","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon T.","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"575_CR1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40263-013-0068-8","volume":"27","author":"S Mi","year":"2013","unstructured":"Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013;27:493\u2013503.","journal-title":"CNS Drugs"},{"key":"575_CR2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","volume":"1","author":"JQ Tran","year":"2014","unstructured":"Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, et al. Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1:e18.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"575_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","volume":"16","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, RENEW Study Investigators, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189\u201399.","journal-title":"Lancet Neurol."},{"key":"575_CR4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0140-6736(72)91155-5","volume":"1","author":"AM Halliday","year":"1972","unstructured":"Halliday AM, McDonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet. 1972;1:982\u20135.","journal-title":"Lancet"},{"key":"575_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00041327-200312000-00010","volume":"23","author":"DC Hood","year":"2003","unstructured":"Hood DC, Odel JG, Winn BJ. The multifocal visual evoked potential. J Neuroophthalmol. 2003;23:279\u201389.","journal-title":"J Neuroophthalmol"},{"key":"575_CR6","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1167\/iovs.09-4577","volume":"51","author":"A Klistorner","year":"2010","unstructured":"Klistorner A, Arvind H, Garrick R, Graham SL, Paine M, Yiannikas C. Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Investig Ophthalmol Vis Sci. 2010;51:2770\u20137.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR7","unstructured":"Creel DJ. Visual evoked potentials. http:\/\/webvision.med.utah.edu\/book\/electrophysiology\/visually-evoked-potentials\/. Accessed 5 Jul 2016."},{"key":"575_CR8","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.clinph.2017.03.047","volume":"128","author":"G Pihl-Jensen","year":"2017","unstructured":"Pihl-Jensen G, Schmidt MF, Frederiksen JL. Multifocal visual evoked potentials in optic neuritis and multiple sclerosis: a review. Clin Neurophysiol. 2017;128:1234\u201345.","journal-title":"Clin Neurophysiol"},{"key":"575_CR9","first-page":"937","volume":"39","author":"AI Klistorner","year":"1998","unstructured":"Klistorner AI, Graham SL, Grigg JR, Billson FA. Multifocal topographic visual evoked potential: improving objective detection of local visual field defects. Investig Ophthalmol Vis Sci. 1998;39:937\u201350.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR10","first-page":"4032","volume":"41","author":"DC Hood","year":"2000","unstructured":"Hood DC, Odel JG, Zhang X. Tracking the recovery of local optic nerve function after optic neuritis: a multifocal VEP study. Investig Ophthalmol Vis Sci. 2000;41:4032\u20138.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10633-014-9467-5","volume":"130","author":"D Narayanan","year":"2015","unstructured":"Narayanan D, Cheng H, Tang RA, Frishman LJ. Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes. Doc Ophthalmol. 2015;130:31\u201341.","journal-title":"Doc Ophthalmol"},{"key":"575_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0301-4738.99638","volume":"61","author":"M Nebbioso","year":"2013","unstructured":"Nebbioso M, Steigerwalt RD, Pecori-Giraldi J, Vingolo EM. Multifocal and pattern-reversal visual evoked potentials vs. automated perimetry frequency-doubling technology matrix in optic neuritis. Indian J Ophthalmol. 2013;61:59\u201364.","journal-title":"Indian J Ophthalmol"},{"issue":"P02","key":"575_CR13","first-page":"245","volume":"80","author":"D Cadavid","year":"2013","unstructured":"Cadavid D, Levin N, Costello F, Rahilly A, Klistorner A. Technical feasibility of implementing multifocal VEP for multicenter clinical trials. Neurology. 2013;80(P02):245.","journal-title":"Neurology."},{"key":"575_CR14","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1167\/iovs.07-0381","volume":"48","author":"A Klistorner","year":"2007","unstructured":"Klistorner A, Graham S, Fraser C, Garrick R, Nguyen T, Paine M, et al. Electrophysiological evidence for heterogeneity of lesions in optic neuritis. Investig Ophthalmol Vis Sci. 2007;48:4549\u201356.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR15","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1352458510371408","volume":"16","author":"A Klistorner","year":"2010","unstructured":"Klistorner A, Arvind H, Garrick R, Yiannikas C, Paine M, Graham SL. Remyelination of optic nerve lesions: spatial and temporal factors. Mult Scler. 2010;16:786\u201395.","journal-title":"Mult Scler."},{"key":"575_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-510X(02)00428-8","volume":"206","author":"SJ Jones","year":"2003","unstructured":"Jones SJ, Brusa A. Neurophysiological evidence for long-term repair of MS lesions: implications for axon protection. J Neurol Sci. 2003;206:193\u20138.","journal-title":"J Neurol Sci"},{"key":"575_CR17","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice. http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf. Accessed 5 Jul 2016."},{"key":"575_CR18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"575_CR19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, et al., on behalf of the IMSVISUAL consortium. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303\u20139.","journal-title":"Neurology."},{"key":"575_CR20","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1167\/iovs.14-14571","volume":"55","author":"D Alshowaeir","year":"2014","unstructured":"Alshowaeir D, Yiannikas C, Garrick R, Parratt J, Barnett MH, Graham SL, et al. Latency of multifocal visual evoked potentials in nonoptic neuritis eyes of multiple sclerosis patients associated with optic radiation lesions. Investig Ophthalmol Vis Sci. 2014;55:3758\u201364.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR21","first-page":"2145","volume":"42","author":"AI Klistorner","year":"2001","unstructured":"Klistorner AI, Graham SL. Electroencephalogram-based scaling of multifocal visual evoked potentials: effect on intersubject amplitude variability. Investig Ophthalmol Vis Sci. 2001;42:2145\u201352.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"575_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1113\/jphysiol.1962.sp006837","volume":"160","author":"DH Hubel","year":"1962","unstructured":"Hubel DH, Wiesel TN. Receptive fields, binocular interaction and functional architecture in the cat\u2019s visual cortex. J Physiol. 1962;160:106\u201354.","journal-title":"J Physiol"},{"key":"575_CR23","doi-asserted-by":"crossref","first-page":"e0122114","DOI":"10.1371\/journal.pone.0122114","volume":"10","author":"A Klistorner","year":"2015","unstructured":"Klistorner A, Vootakuru N, Wang C, Yiannikas C, Graham SL, Parratt J, et al. Decoding diffusivity in multiple sclerosis: analysis of optic radiation lesional and non-lesional white matter. PLoS One. 2015;10:e0122114.","journal-title":"PLoS One"},{"key":"575_CR24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0002-9394(87)90297-2","volume":"104","author":"MA Rosenblatt","year":"1987","unstructured":"Rosenblatt MA, Behrens MM, Zweifach PH, Forman S, Odel JG, Duncan CM, et al. Magnetic resonance imaging of optic tract involvement in multiple sclerosis. Am J Ophthalmol. 1987;104:74\u20139.","journal-title":"Am J Ophthalmol"},{"key":"575_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1755-3768.1991.tb02707.x","volume":"69","author":"JL Frederiksen","year":"1991","unstructured":"Frederiksen JL, Larsson HB, Nordenbo AM, Seedorff HH. Plaques causing hemianopsia or quadrantanopsia in multiple sclerosis identified by MRI and VEP. Acta Ophthalmol (Copenh). 1991;69:169\u201377.","journal-title":"Acta Ophthalmol (Copenh)."},{"key":"575_CR26","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/j.1552-6569.2010.00468.x","volume":"21","author":"HH Dasenbrock","year":"2011","unstructured":"Dasenbrock HH, Smith SA, Ozturk A, Farrell SK, Calabresi PA, Reich DS. Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. J Neuroimaging. 2011;21:e41\u20139.","journal-title":"J Neuroimaging"},{"key":"575_CR27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/brain\/awu335","volume":"138","author":"LJ Balcer","year":"2015","unstructured":"Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain. 2015;138:11\u201327.","journal-title":"Brain"},{"key":"575_CR28","first-page":"205521731664170","volume":"2","author":"MM Gresle","year":"2016","unstructured":"Gresle MM, Liu Y, Kilpatrick TJ, Kemper D, Wu QZ, Hu B, et al. Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. Mult Scler J Exp Transl Clin. 2016;2:2055217316641704.","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"575_CR29","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1212\/NXI.0000000000000417","volume":"5","author":"A Ranger","year":"2017","unstructured":"Ranger A, Ray S, Szak S, Dearth A, Allaire N, Murray R, et al. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol Neuroimmunol Neuroinflamm. 2017;5:e417.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"575_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/aos.12825","volume":"94","author":"D Prins","year":"2016","unstructured":"Prins D, Hanekamp S, Cornelissen FW. Structural brain MRI studies in eye diseases: are they clinically relevant? A review of current findings. Acta Ophthalmol. 2016;94:113\u201321.","journal-title":"Acta Ophthalmol"},{"key":"575_CR31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/jnnp-2013-306902","volume":"85","author":"LJ Balk","year":"2014","unstructured":"Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, et al. A dam for retrograde axonal degeneration in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2014;85:782\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"575_CR32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm1664","volume":"13","author":"S Mi","year":"2007","unstructured":"Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13:1228\u201333.","journal-title":"Nat Med"},{"key":"575_CR33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nn1460","volume":"8","author":"S Mi","year":"2005","unstructured":"Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745\u201351.","journal-title":"Nat Neurosci"},{"key":"575_CR34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1523\/JNEUROSCI.4175-06.2007","volume":"27","author":"X Lee","year":"2007","unstructured":"Lee X, Yang Z, Shao Z, Rosenberg SS, Levesque M, Pepinsky RB, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J Neurosci. 2007;27:220\u20135.","journal-title":"J Neurosci"},{"key":"575_CR35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21581","volume":"65","author":"S Mi","year":"2009","unstructured":"Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65:304\u201315.","journal-title":"Ann Neurol"},{"key":"575_CR36","first-page":"139","volume":"19","author":"B Hu","year":"2013","unstructured":"Hu B, So KF, Pepinsky B, Mi S. Blocking LINGO-1 promotes axonal regeneration in the rat optic nerve crush model. Mult Scler. 2013;19:139.","journal-title":"Mult Scler."},{"key":"575_CR37","first-page":"568354","volume":"2013","author":"A Martins Rosa","year":"2013","unstructured":"Martins Rosa A, Silva MF, Ferreira S, Murta J, Castelo-Branco M. Plasticity in the human visual cortex: an ophthalmology-based perspective. Biomed Res Int. 2013;2013:568354.","journal-title":"Biomed Res Int"},{"key":"575_CR38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jnnp.68.4.441","volume":"68","author":"DJ Werring","year":"2000","unstructured":"Werring DJ, Bullmore ET, Toosy AT, Miller DH, Barker GJ, MacManus DG, et al. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study. J Neurol Neurosurg Psychiatry. 2000;68:441\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"575_CR39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/brain\/awh076","volume":"127","author":"SJ Hickman","year":"2004","unstructured":"Hickman SJ, Toosy AT, Jones SJ, Altmann DR, Miszkiel KA, MacManus DG, et al. Serial magnetization transfer imaging in acute optic neuritis. Brain. 2004;127:692\u2013700.","journal-title":"Brain"},{"key":"575_CR40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn2741","volume":"10","author":"BA Wandell","year":"2009","unstructured":"Wandell BA, Smirnakis SM. Plasticity and stability of visual field maps in adult primary visual cortex. Nat Rev Neurosci. 2009;10:873\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"575_CR41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcjo.2012.05.002","volume":"47","author":"AM Wong","year":"2012","unstructured":"Wong AM. New concepts concerning the neural mechanisms of amblyopia and their clinical implications. Can J Ophthalmol. 2012;47:399\u2013409.","journal-title":"Can J Ophthalmol"},{"key":"575_CR42","first-page":"2779","volume":"27","author":"C Iobbi","year":"2017","unstructured":"Iobbi C, Korte M, Zagrebelsky M. Nogo-66 restricts synaptic strengthening via Lingo1 and the ROCK2-Cofilin pathway to control actin dynamics. Cereb Cortex. 2017;27:2779\u201392.","journal-title":"Cereb Cortex"},{"key":"575_CR43","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/hipo.22565","volume":"26","author":"Y Kellner","year":"2016","unstructured":"Kellner Y, Fricke S, Kramer S, Iobbi C, Wierenga CJ, Schwab ME, et al. Nogo-A controls structural plasticity at dendritic spines by rapidly modulating actin dynamics. Hippocampus. 2016;26:816\u201331.","journal-title":"Hippocampus."},{"key":"575_CR44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00401-013-1108-7","volume":"125","author":"SH Kuo","year":"2013","unstructured":"Kuo SH, Tang G, Louis ED, Ma K, Babji R, Balatbat M, et al. Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol. 2013;125:879\u201389.","journal-title":"Acta Neuropathol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-018-0575-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0575-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:50:11Z","timestamp":1628617811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-018-0575-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0575-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"28 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Biogen (Cambridge, MA, USA). Biogen also provided funding for medical writing support in the development of this paper and for the open access fee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alexander Klistorner has nothing to disclose. Yi Chai was a full-time employee of Biogen during the performance of the clinical trial, data analysis, and initial drafting of the manuscript. Letizia Leocani has received honoraria for consulting and\/or speaking activities from Biogen, Merck, Roche, and Teva; research support from Biogen, Merck, and Novartis; and travel support from Almirall, Biogen, Merck, Novartis, and Roche. Philipp Albrecht has received grants from Biogen, the Dr. Robert Pfleger Foundation, Ipsen, Merz, and Novartis; received non-financial support from Bayer HealthCare, Ipsen, Merck, Merz, Novartis, Roche, and Teva; participated in advisory boards for Allergan, Ipsen, and Merz; and received personal fees from Allergan, Bayer HealthCare, Biogen, Ipsen, Novartis, Roche, and Teva, outside of the submitted work. Orhan Aktas has received advisor fees or honoraria from Almirall, Bayer HealthCare, Biogen, MedImmune, Merck, Novartis, and Teva; and research support from Bayer HealthCare, Biogen, Novartis, Roche, and Teva. Helmut Butzkueven has participated in advisory boards for Biogen, Merck, Novartis, and Teva; received consulting fees from Novartis and Oxford Pharmagenesis; lecture fees from Biogen; received payment for development of educational presentations from Biogen, Merck, and Novartis; and research grants from Biogen and Novartis, outside of the submitted work. Tjalf Ziemssen has received consulting fees from Almirall, Bayer HealthCare, Biogen, Genzyme, GlaxoSmithKline, Merck Serono, MSD, Novartis, Sanofi-Aventis, Synthon, and Teva; and research support from Bayer HealthCare, Biogen, Merck Serono, Novartis, Sanofi-Aventis, and Teva. Focke Ziemssen has received consulting fees from Alimera, Allergan, Bayer HealthCare, Boehringer Ingelheim, Novartis, and Roche; and research support from Novartis. Jette Frederiksen has participated in scientific advisory boards for Almirall, Biogen, Genzyme, Merck Serono, Novartis, Sanofi-Aventis, and Teva; received speaker honoraria from Biogen, Merck Serono, Santhera, and Teva; and been an advisor on preclinical development for Takeda, outside of the submitted work. Lei Xu was a full-time employee of Biogen during the performance of the clinical trial, data analysis, and initial drafting of the manuscript. Diego Cadavid was a full-time employee of Biogen during the performance of the clinical trial and a full-time employee of Fulcrum Therapeutics during submission of the manuscript; the work is not related to his employment in Fulcrum Therapeutics. He has patent WO\u00a02016112270 A1: Lingo-1 antagonists and uses for treatment of demyelinating disorders, which is assigned to Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All investigators obtained approval from their local ethics committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent and the study was performed in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}